Engineers Gate Manager LP trimmed its stake in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 31.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,834 shares of the biopharmaceutical company’s stock after selling 24,315 shares during the period. Engineers Gate Manager LP owned about 0.11% of Sucampo Pharmaceuticals worth $555,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Louisiana State Employees Retirement System raised its holdings in shares of Sucampo Pharmaceuticals by 1.0% during the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 100 shares during the period. First Citizens Bank & Trust Co. acquired a new stake in shares of Sucampo Pharmaceuticals during the second quarter worth $116,000. JPMorgan Chase & Co. acquired a new stake in shares of Sucampo Pharmaceuticals during the second quarter worth $117,000. Karp Capital Management Corp acquired a new stake in shares of Sucampo Pharmaceuticals during the first quarter worth $119,000. Finally, Pinnacle Associates Ltd. acquired a new stake in shares of Sucampo Pharmaceuticals during the second quarter worth $122,000. Institutional investors and hedge funds own 55.44% of the company’s stock.

In related news, insider Jason Patrick Meyenburg purchased 4,000 shares of Sucampo Pharmaceuticals stock in a transaction that occurred on Wednesday, September 6th. The stock was bought at an average price of $12.13 per share, for a total transaction of $48,520.00. Following the completion of the transaction, the insider now owns 30,228 shares in the company, valued at $366,665.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $12.00, for a total transaction of $12,000,000.00. The disclosure for this sale can be found here. 4.13% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Shares Sold by Engineers Gate Manager LP” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/17/sucampo-pharmaceuticals-inc-scmp-shares-sold-by-engineers-gate-manager-lp.html.

A number of equities research analysts recently commented on the stock. BidaskClub lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 5th. Maxim Group set a $23.00 target price on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. TheStreet downgraded shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research report on Wednesday, August 2nd. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Finally, Roth Capital set a $30.00 target price on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $17.63.

Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) opened at 12.15 on Friday. The company’s 50 day moving average is $11.24 and its 200 day moving average is $10.69. The company’s market cap is $562.85 million. Sucampo Pharmaceuticals, Inc. has a one year low of $9.30 and a one year high of $17.55.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.06. The company had revenue of $59.90 million during the quarter, compared to analyst estimates of $56.44 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The firm’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.24 earnings per share. On average, equities analysts predict that Sucampo Pharmaceuticals, Inc. will post $1.02 earnings per share for the current year.

Sucampo Pharmaceuticals Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.